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Abstract  Candida  africana  taxonomical  status  is  controversial.  It  was  proposed  as  a  separate
species  within  the  Candida  albicans  species  complex;  however,  phylogenetic  analyses  suggested
that it  is  an  unusual  variety  of  C.  albicans.  The  prevalence  of  C.  albicans-related  species
(Candida  dubliniensis  and  C.  africana)  as  vulvovaginal  pathogens  is  not  known  in  Argentina.
Moreover,  data  on  antifungal  susceptibility  of  isolates  causing  vulvovaginal  candidiasis  is  scarce.
The aims  of  this  study  were  to  establish  the  prevalence  of  C.  dubliniensis  and  C.  africana  in  vagi-
nal samples  and  to  evaluate  the  antifungal  susceptibilities  of  vaginal  C.  albicans  species  complex
strains. We  used  a  molecular-based  method  coupled  with  a  new  pooled  DNA  extraction  method-
ology to  differentiate  C.  dubliniensis  and  C.  africana  in  a  collection  of  287  strains  originally
identiﬁed as  C.  albicans  isolated  from  an  Argentinian  hospital  during  2013.  Antifungal  suscepti-
bilities to  ﬂuconazole,  clotrimazole,  itraconazole,  voriconazole,  nystatin,  amphotericin  B  and
terbinaﬁne  were  evaluated  by  using  the  CLSI  M27-A3  and  M27-S4  documents.  Of  the  287  isolates,
4 C.  dubliniensis  and  one  C.  africana  strains  (1.39%  and  0.35%  prevalence,  respectively)  were
identiﬁed. This  is  the  ﬁrst  description  of  C.  africana  in  Argentina  and  its  identiﬁcation  was  con-
ﬁrmed by  sequencing  the  ITS2  region  and  the  hwp1  gene.  C.  dubliniensis  and  C.  africana  strains
showed very  low  MIC  values  for  all  the  tested  antifungals.  Fluconazole-reduced-susceptibility
and azole  cross-resistance  were  observed  in  3.55%  and  1.41%  of  the  C.  albicans  isolates,  respec-
tively. These  results  demonstrate  that  antifungal  resistance  is  still  a  rare  phenomenon  in  this
kind of  isolates.na  de  Microbiología.  Published  by  Elsevier  España,  S.L.U.  This  is
r  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/© 2015  Asociación  Argenti
an open  access  article  unde
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Prevalencia  y  sensibilidad  a  los  antifúngicos  de  Candida  albicans  y sus  especies
relacionadas,  Candida  dubliniensis  y Candida  africana  aisladas  de  muestras
vulvovaginales  en  un  hospital  de  Argentina
Resumen  La  clasiﬁcación  taxonómica  de  Candida  africana  está  en  discusión,  es  considerada
una nueva  especie  dentro  del  complejo  C.  albicans  o  una  variedad  inusual  de  C.  albicans.  La
prevalencia  de  las  especies  relacionadas  a  C.  albicans  (C.  dubliniensis  y  C.  africana)  como
agentes  de  vulvovaginitis  en  Argentina  se  desconoce.  Los  objetivos  de  este  trabajo  fueron
determinar  la  prevalencia  de  C.  dubliniensis  y  C.  africana  en  muestras  vaginales  y  evaluar
la sensibilidad  a  los  antifúngicos  de  aislamientos  vaginales  de  las  especies  del  complejo  C.
albicans. Para  diferenciar  C.  dubliniensis  y  C.  africana  utilizamos  un  método  molecular  asociado
a un  nuevo  método  de  extracción  de  ADN.  Se  utilizó  una  colección  de  287  cepas  originalmente
identiﬁcadas  como  C.  albicans  aisladas  durante  2013  en  un  hospital  de  Argentina.  Se  evaluó
la sensibilidad  a  ﬂuconazol,  clotrimazol,  itraconazol,  voriconazol,  nistatina,  anfotericina  B  y
terbinaﬁna  utilizando  los  documentos  M27-A3  y  M27-S4  del  CLSI.  De  los  287  aislamientos,  se
identiﬁcaron  4  C.  dubliniensis  y  1  C.  africana  (1,39  y  0,35%  de  prevalencia,  respectivamente).
Esta es  la  primera  descripción  de  C.  africana  en  Argentina.  Su  identiﬁcación  fue  conﬁrmada  por
secuenciación  de  la  región  ITS2  y  del  gen  hwp1.  Las  cepas  identiﬁcadas  como  C.  dubliniensis
y C.  africana  mostraron  valores  de  CIM  muy  bajos  para  todos  los  antifúngicos  probados.  En  los
aislamientos  de  C.  albicans,  la  sensibilidad  reducida  al  ﬂuconazol  y  la  resistencia  cruzada  a  todos
los azoles  se  observó  en  el  3,55%  y  el  1,41%,  respectivamente.  Estos  resultados  demuestran  que
la resistencia  a  los  antifúngicos  es  todavía  un  fenómeno  raro  en  este  tipo  de  aislamientos.
© 2015  Asociación  Argentina  de  Microbiología.  Publicado  por  Elsevier  España,  S.L.U.  Este  es
un artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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ore  than  twenty  different  species  of  Candida  have
een  reported  as  human  pathogens14,20.  However,  Candida
lbicans  is  the  most  common  human  fungal  pathogen  and  the
ost  studied  of  all  Candida  species8,10,15,17,20.  C.  albicans  has
 great  degree  of  variability  and  some  of  the  ﬁrstly  known
s  ‘‘atypical’’  C.  albicans  isolates  were  later  considered
s  related  species.  That  is  the  case  with  the  well-known
andida  dubliniensis30.  Other  ‘‘atypical’’  C.  albicans  con-
idered  as  separated  species  are  now  described  as  varieties
e.g.  C.  albicans  var.  stellatoidea) and  included  as  one  of
he  173  C.  albicans  synonyms10.  The  most  recently  described
.  albicans  related  species  is  Candida  africana31.  The
rst  C.  africana  strain  was  isolated  from  African  patients
uffering  from  vulvovaginal  candidiasis  (VVC)  and  ﬁrstly
onsidered  ‘‘atypical’’  C.  albicans  strains32. Later,  it  was
roposed  as  a  new  species  based  on  morphological,  bio-
hemical  and  physiological  differences  which  include  its
nability  to  assimilate  glucosamine  and  N-acetylglucosamine
nd  its  impossibility  to  form  chlamydospores  on  corn
eal  agar24,31.  Odds  et  al.  in  2007  included  C.  africana
n  C.  albicans  clade  13  and  supported  a  varietal  status
C.  albicans  var.  africana)16.  One  year  later,  the  same
roup  included  several  C.  africana  strains  in  a  group  highly
istinct  from  the  majority  of  C.  albicans  together  with
andida  stellatoidea  type  I  and  other  sucrose-negative
9typical  C.  albicans  isolates .  These  facts  support  the  con-
roversial  taxonomic  status  of  these  isolates.
The  prevalence  of  these  C.  albicans  related  species  as
gents  of  VVC  is  not  known  in  Argentina.  Moreover,  data  on
m
9
sntifungal  susceptibility  patterns  of  isolates  causing  VVC  are
carce12.
The  aim  of  this  study  was  to  establish  the  preva-
ence  of  C.  dubliniensis  and  C.  africana  in  a  collection
f  yeasts  originally  identiﬁed  as  C.  albicans  and  isolated
rom  VVC  using  a  molecular-based  method  coupled  with
 pooled  DNA  extraction  methodology.  Additionally,  we
valuated  the  antifungal  susceptibility  patterns  of  these
trains.
aterials and methods
east  strains
 total  of  287  strains  were  included  in  this  study.  All  iso-
ates  were  obtained  from  patients  having  vaginal  infection
ymptoms  attending  the  José  María  Cullen  Hospital  (Santa
e  --  Argentina)  during  2013.  All  the  strains  were  iden-
iﬁed  as  C.  albicans  by  germ  tube  formation  in  human
erum  and  their  ability  to  form  green  color  colonies
n  CHROMAgar  CandidaTM (Biomerieux  --  Medica-Tec  SRL,
uenos  Aires,  Argentina).  All  yeast  isolates  were  referred  to
he  ‘‘Micología  y  Diagnóstico  Molecular’’ Laboratory  (CON-
CET  Universidad  Nacional  del  Litoral)  where  they  were
tored  and  identiﬁed  in  accordance  with  morphology  and
arbohydrate  assimilation  and  fermentation11 and  by  a
olecular  procedure  as  described  below.  C.  albicans  ATCC
0028  and  C.  dubliniensis  NCPF  3949  were  used  as  control
trains.
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Table  1  Oligonucleotide  primers  used  in  this  study
Oligonucleotide  Target  gene  5′ →  3′ sequence  Primer  orientation
CR-Fa HPW1  GCTACCACTTCAGAATCATCATC  Sense
CR-Ra HPW1  GCACCTTCAGTCGTAGAGACG  Antisense
ITS1b ITS  TCCGTAGGTGAACCTGCGG  Sense
ITS4b ITS  TCCTCCGCTTATTGATATGC  Antisense
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Molecular  identiﬁcation  by  using  hwp1  gene
amplicon length
A  PCR  method  based  on  hwp1  gene  ampliﬁcation  to  differen-
tiate  C.  albicans,  C.  africana  and  C.  dubliniensis  was  used.
This  method  identiﬁed  the  three  species  through  the  diffe-
rences  in  sizes  of  the  obtained  PCR  fragments:  569  bp,  700  bp
and  941  bp,  respectively,  when  the  DNA  of  C.  dubliniensis,
C.  africana  and  C.  albicans  DNA  was  used  as  template23.
Primers  are  displayed  in  Table  1.
Individual  and  pooled  DNA  extraction
The  isolates  were  individually  grown  in  1  ml  of  YPD  broth
(1%  yeast  extract,  2%  Bacto  peptone,  2%  dextrose)  at  35 ◦C
for  24  h  and  constant  shaking  (200  rpm).  Then,  200  l  of
10  individual  cultures  were  mixed  to  obtain  2  ml  yeast
cells  pools  from  which  the  pooled  DNA  was  extracted.  The
remaining  800  l  of  yeast  cultures  were  kept  at  −20 ◦C  and
used  later  to  obtain  individual  genomic  DNAs  if  necessary.
Yeast  DNAs  (individual  and  pooled)  were  extracted  using  a
phenol-based  procedure26.
High-throughput  screening  to  rapidly  identify  C.
africana  and  C.  dubliniensis  in  a  strain  collection
Originally,  Romeo  et  al.23 designed  their  method  to  iden-
tify  strains  using  individual  DNAs.  In  an  effort  to  establish
a  high  throughput  screening  method  to  study  fungal  collec-
tions  we  decided  to  use  the  same  PCR  technique  but  using
pooled  DNAs  (containing  DNAs  isolated  from  ten  different
strains).  The  presence  of  C.  africana  or  C.  dubliniensis  DNA
was  suspected  when  more  than  one  PCR  band  was  observed.
To  uncover  C.  dubliniensis  and  C.  africana,  we  extracted
individual  DNA  from  all  the  pools  showing  multiple  bands
(941  bp  plus  569  bp  and/or  700  bp)  and  the  hwp1  PCR  was
repeated  using  individual  DNAs  as  templates.  Additionally,
we  extracted  individual  DNA  for  10  randomly  chosen  pools
showing  one  941  bp  band  (100  DNAs  in  total)  and  repeated
the  hwp1  PCR  to  conﬁrm  the  speciﬁcity  of  the  technique.
Identiﬁcation  conﬁrmation
All  the  strains  identiﬁed  as  C.  dubliniensis  or  C.  africana
by  hwp1  gene  ampliﬁcation  were  subsequently  identiﬁed  by
sequencing  the  5.8S  RNA  gene  and  adjacent  internal  tran-
scribed  spacer  1  and  2  regions  (ITS1  and  ITS2)  and  the  hwp1
gene2,35.  Primers  are  displayed  in  Table  1.
N
T
intifungal  susceptibility  testing
ntifungal  drugs  tested  were  ﬂuconazole  (FLC),  itraconazole
ITC),  voriconazole  (VRC),  clotrimazole  (CLT),  terbinaﬁne
TRB),  anfotericin  B  (AMB)  and  nystatin  (NYS)  (all  purchased
rom  Sigma--Aldrich  Química  --  Buenos  Aires,  Argentina).
rug  selection  was  performed  based  on  the  treatment
ptions  (topical,  vaginal  ovules  and  systemic  presenta-
ions)  available  at  José  María  Cullen  Hospital  (Santa  Fe,
rgentina).  Although  AMB  is  not  used  to  treat  vaginal  infec-
ions,  it  was  added  to  the  list  of  tested  drugs  to  assess  if
t  was  possible  to  use  it  as  an  in  vitro  surrogate  marker
or  NYS  resistance  since  AMB  susceptibility  testing  is  stan-
ardized  by  CLSI  and  both  are  polyenes5,6. Inoculums  of
ll  the  isolates  were  obtained  according  to  CLSI  document
27-A3.  Result  interpretations  were  performed  according  to
LSI  documents  M27-A3  and  M27-S4.  FLC,  ITC  and  AMB  MIC
icrotitration  plates  were  produced  following  CLSI  M27-A3
uidelines5,6.  In  addition,  TRB,  CLT  and  NYS  were  diluted  in
imethyl  sulfoxide  and  the  ﬁnal  concentrations  ranged  from
 to  0.015  g/ml.  Since  there  are  no  MIC  limit  ranges  for
icrodilution  tests  for  these  antifungal  agents,  the  quality
ontrol  strains  Candida  parapsilosis  ATCC  22019  and  Candida
rusei  ATCC  6258  were  subjected  to  twenty  MIC  repeti-
ions  on  different  days  (results  are  displayed  in  Table  2).
fterwards,  this  MIC  data  was  added  to  earlier  MIC  results
btained  by  our  group8 and  were  used  as  a control  of  the
roduced  plates.
ata  collection  and  statistical  analysis
he  MIC  data  presented  here  are  expressed  as  geometric
eans  (GMs)  of  three  experiments  performed  on  different
ays.  The  off-scale  MICs  were  converted  to  the  next  concen-
ration  up  or  down  in  order  to  be  included  in  the  analysis.  MIC
alues  were  approximated  to  a  normal  distribution  by  trans-
orming  them  into  log2 values.  GMs  were  used  to  statistically
ompare  MIC  values  and  MIC  log2 values  were  used  to  esta-
lish  susceptibility  differences  between  strains.  To  establish
igniﬁcant  levels  of  MIC  differences,  a  one-way  ANOVA  test
ith  Bonferroni’s  correction  for  multiple  comparisons  was
sed.  A  P  value  ≤0.05  was  considered  signiﬁcant.  This  study
as  approved  by  the  School  of  Biochemistry  (Universidad
acional  del  Litoral)  and  JM  Cullen  ethics  committees.ucleotide  sequence  accession  numbers
he  C.  africana  strain  hwp1  gene  sequence  was  deposited
n  GenBank  under  accession  number  KR704898.
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Table  2  Terbinaﬁne,  clotrimazole  and  nystatin  MIC  ranges  for  control  strains  obtained  following  CLSI  M27-A3  and  M27-S4
document recommendations
MIC  range  (g/ml)a
Terbinaﬁne  Clotrimazole  Nystatin
C.  parapsilosis  ATCC  22019  0.03--0.12  0.015--0.03  0.12--0.25
C. krusei  ATCC  6258  >--4  0.015--0.06  0.50--1.00
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esults
dentiﬁcation  and  prevalence  of  C.  dubliniensis
nd C.  africana
ith  the  intention  of  evaluating  the  prevalence  and  poten-
ial  clinical  signiﬁcance  of  C.  dubliniensis  and  C.  africana  in
aginal  samples  from  Santa  Fe  city,  we  molecularly  identify
he  287  isolates  received  (previously  identiﬁed  by  pheno-
ypic  methods  as  C.  albicans)  by  using  the  ampliﬁcation  of
he  hwp1  gene  using  a  single  primer  pair23. We  employed
 higher  throughput  methodology  using  DNA  pools  obtained
rom  ten  different  isolates  as  templates.  When  pooled  DNAs
ere  used,  the  presence  of  non-C. albicans  was  suspected
hen  two  or  more  bands  appeared  in  the  electrophoresis.
 941  bp  fragment  along  with  a  569  bp  fragment  demon-
trated  the  presence  of  at  least  one  C.  albicans  and  one
.  dubliniensis  strain  in  the  DNA  pool  while  the  presence  of
 700  bp  fragment  proved  the  existence  of  at  least  one  C.
fricana  strain  in  the  pool  (Fig.  1).  The  presence  of  two  PCR
ands  was  observed  in  ﬁve  out  of  the  29  DNA  pools.  Four
howed  a  941--569  bp-double  band  and  the  ﬁfth  showed  a
41--700  bp-band  pair  representing  the  presence  of  at  least
our  C.  dubliniensis  and  one  C.  africana  strains.  These  ﬁve
NA  pools  were  subsequently  studied  to  conﬁrm  the  results.
ndividual  DNAs  were  used  as  PCR  template  plate  to  amplify
he  hwp1  gene.  Four  C.  dubliniensis  and  one  C.  africana
ere  identiﬁed.  Altogether,  we  obtained  the  same
esults  using  pooled  and  individual  DNA  extraction:  four
.  dubliniensis  and  one  C.  africana  strains  out  of
i
s
a
a
A M 1 2 3 4 5 6
1000
700
500
300
igure  1  (A)  Electrophoresis  of  the  hwp1  gene  PCR  using  DNA  pool
, C.  albicans  control  strain  (ATCC  90028).  Lane  2,  C.  dubliniensis  c
ands. Lane  3:  941  bp  and  700  bp  (C.  albicans  and  C.  africana).  Lan
C. albicans  and  C.  dubliniensis).  (B)  Electrophoresis  on  1  %  agarose
isplayed in  lane  3  --  (A)).  Lane  M,  100  bp  size  marker.  Lane  1,  C.
ontrol strain  (NCPF  3949).  Lane  3,  C.  africana  (Strain  LMDM  678).  Lork plus 20 repetitions performed in a previous work conducted
87  studied  isolates  (1.39%  and  0.35%  prevalence,  respec-
ively).  The  identiﬁcation  of  these  strains  was  conﬁrmed
y  ITS  and  hwp1  sequencing.  The  ITS  obtained  sequences
ere  compared  with  the  published  ITS  signature  sequences
rom  C.  albicans  (variants  I  to  IV)  (Gene  bank  aa.  numbers:
P675686.1,  HQ876051.1,  KP675529.1  and  KP675666.1,
espectively),  C.  dubliniensis  (variants  I  and  II)  (aa.  num-
ers:  AB035589.1  and  KP131696.1,  respectively),  C.  albicans
ar.  stellatoidea  (aa.  numbers:  AJ853768.1)  and  C.  africana
aa.  numbers:  AY342214.1)2 (Fig.  2A).  The  hwp1  gene
equences  of  our  non-albicans  strains  showed  the  char-
cteristic  nt.  gaps  (372  bp  and  241  bp  difference  for  C.
ubliniensis  and  C.  africana,  respectively)  (Fig.  2B).
Phenotypically,  our  C.  africana  strain  differed  from  the
.  albicans  control  strains  in  its  inability  to  form  chlamy-
ospores  on  corn  meal  agar,  to  assimilate  trehalose  and
o  grow  at  42 ◦C.  However,  it  developed  green  colonies  on
HROMagar  and  formed  germ  tubes  under  regular  condi-
ions  (2  h  at  37 ◦C).  Our  C.  africana  showed  a  lower  rate
f  germ  tube  formation  when  compared  to  C.  albicans  and
.  dubliniensis  control  strains.
ntifungal  susceptibility  testing
he  in  vitro  activities  of  the  tested  antifungal  drugs
re  summarized  in  Table  3.  All  non-C. albicans  strains
ncluded  in  this  study  (4  C.  dubliniensis  and  the  C.  africana)
howed  very  low  MIC  values  for  all  the  tested  antifungal
gents.  Similarly,  antifungal  drugs  showed  good  in  vitro
ctivity  against  the  majority  of  the  remaining  282  isolates
B M 1 2 3 4
700
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100
s  resolved  on  1  %  agarose  gel.  Lane  M,  100  bp  size  marker.  Lane
ontrol  strain  (NCPF  3949).  Lanes  3--6,  DNA  pools  showing  hwp1
es  4  and  5:  941  bp  (C.  albicans  alone).  Lane  6:  941  and  569  bp
 gel  of  the  hwp1  PCR  using  individual  DNAs  (from  the  DNA  pool
 albicans  control  strain  (ATCC  90028).  Lane  2,  C.  dubliniensis
ane  4,  C.  albicans  (Strain  LMDM  679).
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Figure  2  (A)  Sequence  alignments  of  the  35-bp  portion  of  the  ITS2  region  allowing  to  differentiate  the  four  C.  albicans  variants,
the two  C.  dubliniensis  types,  C.  albicans  var.  stellatoidea  and  C.  africana2.  C.  africana  strain  LMDM  678  showed  no  differences
with the  C.  africana  type  strain.  Dots  indicate  conserved  nucleotides;  gaps  are  represented  as  hyphens  and  nucleotide  differences
are displayed  as  letters.  (B)  Sequence  alignments  of  regions  of  the  hwp1  gene  where  gaps  were  encountered.  The  upper  line
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adisplays C.  albicans  hwp1  (GenBank  accession  number  U6420
africana LMDM  678  (KR704898)  and  fourth  line:  C.  dubliniensis  
(C.  albicans).  The  most  potent  azole  was  CLT  showing  the
lowest  MIC  values  (GM  =  0.02  g/ml,  MIC90  =  0.03  g/ml)  and
only  thirteen  strains  showed  CLT  MIC  value  ≥0.25  g/ml.
FLC  was  the  tested  drug  with  the  widest  range  of  MIC
values  (0.06--64.00  g/ml).  Reduced  susceptibility  to  FLC
was  observed  in  ten  C.  albicans  strains  out  of  the  282
studied  (3.55  %).  Of  these  ten  strains,  three  were  FLC
susceptible-dose  dependent  while  seven  were  resistant
to  FLC  (three  strains  were  exclusively  resistant  to  FLC
and  four  strains  were  azole-cross-resistant).  Concerning
the  oral  triazoles,  ITC  and  VRC  showed  very  good  in  vitro
activity  (GM  =  0.03  g/ml  and  a  MIC90  =  0.06  g/ml  for  ITC
and  GM  =  0.021  g/ml  and  a  MIC90  =  0.03  g/ml).  There
were  only  four  (1.41  %)  C.  albicans  strains  showing  high  ITC
and  VRC  MIC  values  (≥4.00  g/ml).  These  strains  showed
FLC  cross-resistance  (FLC  MIC  ≥16  g/ml)  and  high  CLT  MIC
values  (≥0.25  g/ml).
Both  tested  polyenes  showed  a  narrow  range  of  MIC  va-
lues  (0.03--0.25  g/ml  for  both  AMB  and  NYS)  and  showed
no  differences  in  in  vitro  activity  (p  =  0.43).  None  of  the  287
strains  showed  high  MIC  values  for  NYSor  for  AMB.  Further-
more,  TRB  was  the  least  active  drug  against  the  isolates
tested  (GM  =  6.25  g/ml  and  MIC90  =  8.00  g/ml).  However,
the  ﬁve  non-albicans  isolates  including  four  C.  dubliniensis
and  one  C.  africana  showed  slightly  lower  TRB  MIC  values,
ranging  from  1.00  to  2.00  g/ml  (p  =  0.42).
DiscussionIn  the  present  study,  we  used  the  ampliﬁcation  of  the
hwp1  gene  to  evaluate  the  presence  of  C.  africana  and  C.
dubliniensis  among  vaginal  isolates  identiﬁed  as  C.  albicans
in  accordance  with  their  phenotypic  characteristics.  We
t
l
V
s second  line:  C.  africana  hwp1  (EU477610.1);  third  line:  C.
2273.1).
emonstrated  that  the  ampliﬁcation  of  the  hwp1  gene  using
ooled  DNAs  was  as  efﬁcient  as  using  individual  DNAs  to  dif-
erentiate  C.  dubliniensis  and  C.  africana  from  C.  albicans.
hus,  this  methodology  can  be  used  as  a  high  throughput
creening  method  to  study  fungal  collections.
Earlier  reports  from  Europe  and  Africa  demonstrated  that
.  africana  represented  more  than  5%  of  the  C.  albicans
pecies  complex  isolated  from  female  genital  specimens  and
hat  it  was  more  prevalent  than  C.  dubliniensis  in  this  type
f  samples2,13,25,31.  Conversely,  in  our  patients,  C.  africana
as  less  prevalent  than  C.  dubliniensis  (0.35%  and  1.39%,
espectively).
To  the  best  of  our  knowledge,  the  described  C.  africana
train  is  the  ﬁrst  autochthonous  Argentinian  isolate  reported
o  far.  The  strain  was  identiﬁed  as  C.  africana  by  two
ifferent  sequencing-based  methods  (ITS  and  hwp1  gene
equencing).  Phenotypically,  our  C.  africana  strain  showed
haracteristics  that  coincide  with  previous  reports2,25,33.  We
bserved  a  lower  ﬁlamentation  rate  in  serum  for  the  C.
fricana  isolate.  This  fact  was  reported  also  by  Borman
t  al2. These  authors  linked  this  lower  hyphal  formation
apacity  to  the  reduced  virulence  of  C.  africana  and  its
arrow  anatomical  niche.
When  antifungal  susceptibility  was  analyzed,  our  C.
fricana  and  C.  dubliniensis  strains  showed  low  MIC  values
o  all  the  antifungal  tested.  Moreover,  reduced  susceptibi-
ity  was  rare  in  all  the  Candida  strains  studied,  reinforcing
he  idea  that  C.  albicans  and  its  related  species  isolated
rom  VVC  patients  are  usually  susceptible  to  antifungal
gents7,8,12,21,22,29.  In  the  case  of  azoles,  CLT  and  ITC  showed
he  highest  potency  and  FLC  MIC  GMs  values  were  simi-
ar  to  those  obtained  in  previous  reports  for  yeast  causing
VC1,3,22.  However,  3.55  %  (10/282)  of  the  C.  albicans  strains
howed  FLC  reduced  susceptibility  (three  susceptible-dose
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ependent),  three  FLC-resistant  and  four  of  these  strains
ere  azole  cross-resistant.  This  FLC  resistance  frequency  in
.  albicans  isolated  from  VVC  was  higher  than  that  men-
ioned  in  other  published  reports,  where  there  was  no  FLC
esistance12,21,29.
These  susceptibility  patterns  and  the  wide  range  of  FLC
IC  values  observed  in  our  strain  collection  allow  us  to
nfer  that  in  Santa  Fe  city  several  molecular  mechanism  of
zole  resistance  may  coexist  and  antifungal  resistance  could
ecome  a  problem  in  the  future4,18,19,27,28,34.
Here  we  report  the  ﬁrst  Argentinian  C.  africana  isolate
nd  a  high-throughput  screening  method  to  uncover  the
resence  of  this  newly  described  species  variety  in  a  col-
ection  of  yeasts  isolated  from  VVC.  We  also  demonstrate
hat  C.  albicans  related  species  have  low  prevalence  in  our
egion.  Moreover,  antifungal  resistance  seems  not  to  be  a
erious  concern  in  Santa  Fe  city  region  (Argentina).  However,
VC  treatment  should  be  supported  by  laboratory  results.
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